ECM stiffness inhibits ferroptosis to promote HCC progression via the FOXA1-CDON-HMGB1/p53 pathway.
- 1Department of Gastroenterology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei, 430022, PR China.
- 2Department of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan City, Hubei, 430022, PR China.
Abstract
The progression of hepatocellular carcinoma (HCC) is closely associated with the physical microenvironment, particularly the stiffness of the extracellular matrix (ECM). However, the molecular mechanisms by which the ECM influences HCC progression remain unclear. We demonstrate that a stiff ECM promotes HCC progression and identify the key regulatory molecule CDON using a polyacrylamide hydrogel model, transcriptome sequencing, and other assays. A gradual increase in ECM stiffness upregulates CDON expression, and elevated CDON levels are associated with poor prognosis. CDON is highly expressed in HCC cells and tissues, where it enhances invasion, metastasis, and proliferation. ECM stiffness regulates HCC progression through CDON. In the cytoplasm, CDON binds to HMGB1, reducing HMGB1 levels in both the cytoplasm and nucleus. This reduction leads to the release of p53 from the nucleus into the cytoplasm and its degradation through the ubiquitination-proteasome pathway, weakening p53's transcriptional repression of SLC7A11 and thereby inhibiting ferroptosis, which promotes sorafenib chemotherapy resistance in HCC cells. Additionally, stiff ECM promotes the nuclear translocation of YAP1 via integrins. Once in the nucleus, YAP1 binds to the transcription factor FOXA1 to regulate CDON transcription. This study demonstrates that stiff ECM serves as an indicator for differentiating HCC progression and chemotherapy resistance. Targeting the "CDON-ferroptosis" axis may offer a novel combined treatment strategy.
Related
- CST1 stabilizes GPX4 to suppress ferroptosis and promote bladder cancer progression
- The m6A/METTL3 modifies USP11 to promote Warburg effect progression of colon cancer undifferentiated by HIF-1α/YAP signaling pathway
- CLIC4 inhibits the progression of non-small cell lung cancer by suppressing the MAPK pathway
- Gastrodin inhibits neuronal ferroptosis by regulating mir-455–5p/ACSL4 pathway after stroke via exosome
- SURF4 regulates RRM2 to activate the PI3K/AKT pathway and promote malignant progression in hepatocellular carcinoma
BibTeX
@article{song2026stiffness,
title = {{ECM stiffness inhibits ferroptosis to promote HCC progression via the FOXA1-CDON-HMGB1/p53 pathway.}},
author = {Qianben Song and Xilin Ye and Xin Mao and Lumiao Zhang and Mengjia Jing and Yu Fu and Wei Yan},
journal = {International journal of biological sciences},
year = {2026},
month = oct,
doi = {10.7150/ijbs.129038},
url = {https://europepmc.org/article/MED/42910293},
note = {CC BY},
}
RIS
TY - JOUR
TI - ECM stiffness inhibits ferroptosis to promote HCC progression via the FOXA1-CDON-HMGB1/p53 pathway.
AU - Qianben Song
AU - Xilin Ye
AU - Xin Mao
AU - Lumiao Zhang
AU - Mengjia Jing
AU - Yu Fu
AU - Wei Yan
PY - 2026
DA - 2026/10/09
JO - International journal of biological sciences
DO - 10.7150/ijbs.129038
UR - https://europepmc.org/article/MED/42910293
AB - The progression of hepatocellular carcinoma (HCC) is closely associated with the physical microenvironment, particularly the stiffness of the extracellular matrix (ECM). However, the molecular mechanisms by which the ECM influences HCC progression remain unclear. We demonstrate that a stiff ECM promotes HCC progression and identify the key regulatory molecule CDON using a polyacrylamide hydrogel model, transcriptome sequencing, and other assays. A gradual increase in ECM stiffness upregulates CDON expression, and elevated CDON levels are associated with poor prognosis. CDON is highly expressed in HCC cells and tissues, where it enhances invasion, metastasis, and proliferation. ECM stiffness regulates HCC progression through CDON. In the cytoplasm, CDON binds to HMGB1, reducing HMGB1 levels in both the cytoplasm and nucleus. This reduction leads to the release of p53 from the nucleus into the cytoplasm and its degradation through the ubiquitination-proteasome pathway, weakening p53's transcriptional repression of SLC7A11 and thereby inhibiting ferroptosis, which promotes sorafenib chemotherapy resistance in HCC cells. Additionally, stiff ECM promotes the nuclear translocation of YAP1 via integrins. Once in the nucleus, YAP1 binds to the transcription factor FOXA1 to regulate CDON transcription. This study demonstrates that stiff ECM serves as an indicator for differentiating HCC progression and chemotherapy resistance. Targeting the "CDON-ferroptosis" axis may offer a novel combined treatment strategy.
SN - 1449-2288
ER -